FABP4 and acute myeloid leukemia: Various therapeutic strategies have been explored to target AML, including the inhibition of FABP4 and carnitine palmitoyltransferase 1a (CPT1a), an enzyme responsible for lipid transport into mitochondria for β-oxidation.